These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 31925805)

  • 1. Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities.
    Goeppert B; Folseraas T; Roessler S; Kloor M; Volckmar AL; Endris V; Buchhalter I; Stenzinger A; Grzyb K; Grimsrud MM; Gornicka B; von Seth E; Reynolds GM; Franke A; Gotthardt DN; Mehrabi A; Cheung A; Verheij J; Arola J; Mäkisalo H; Eide TJ; Weidemann S; Cheville JC; Mazza G; Hirschfield GM; Ponsioen CY; Bergquist A; Milkiewicz P; Lazaridis KN; Schramm C; Manns MP; Färkkilä M; Vogel A; ; Boberg KM; Schirmacher P; Karlsen TH
    Hepatology; 2020 Oct; 72(4):1253-1266. PubMed ID: 31925805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutational spectrum and precision oncology for biliary tract carcinoma.
    Lin J; Cao Y; Yang X; Li G; Shi Y; Wang D; Long J; Song Y; Mao J; Xie F; Bai Y; Zhang L; Yang X; Wan X; Wang A; Guan M; Zhao L; Hu K; Pan J; Huo L; Lu X; Mao Y; Sang X; Zhang H; Wang K; Wang X; Zhao H
    Theranostics; 2021; 11(10):4585-4598. PubMed ID: 33754015
    [No Abstract]   [Full Text] [Related]  

  • 3. Primary Sclerosing Cholangitis-Associated Cholangiocarcinoma Demonstrates High Intertumor and Intratumor Heterogeneity.
    Kamp EJCA; Peppelenbosch MP; Doukas M; Verheij J; Ponsioen CY; van Marion R; Bruno MJ; Groot Koerkamp B; Dinjens WNM; de Vries AC
    Clin Transl Gastroenterol; 2021 Oct; 12(10):e00410. PubMed ID: 34608877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole-exome sequencing reveals novel cancer genes and actionable targets in biliary tract cancers in primary sclerosing cholangitis.
    Grimsrud MM; Forster M; Goeppert B; Hemmrich-Stanisak G; Sax I; Grzyb K; Braadland PR; Charbel A; Metzger C; Albrecht T; Steiert TA; Schlesner M; Manns MP; Vogel A; Yaqub S; Karlsen TH; Schirmacher P; Boberg KM; Franke A; Roessler S; Folseraas T
    Hepatol Commun; 2024 Jul; 8(7):. PubMed ID: 38967597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic alterations during the neoplastic cascade towards cholangiocarcinoma in primary sclerosing cholangitis.
    Kamp EJ; Dinjens WN; Doukas M; van Marion R; Verheij J; Ponsioen CY; Bruno MJ; Groot Koerkamp B; Trivedi PJ; Peppelenbosch MP; de Vries AC
    J Pathol; 2022 Nov; 258(3):227-235. PubMed ID: 35897137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biliary dysplasia, cell proliferation and nuclear DNA-fragmentation in primary sclerosing cholangitis with and without cholangiocarcinoma.
    Bergquist A; Glaumann H; Stål P; Wang GS; Broomé U
    J Intern Med; 2001 Jan; 249(1):69-75. PubMed ID: 11168786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p16INK4a promoter mutations are frequent in primary sclerosing cholangitis (PSC) and PSC-associated cholangiocarcinoma.
    Taniai M; Higuchi H; Burgart LJ; Gores GJ
    Gastroenterology; 2002 Oct; 123(4):1090-8. PubMed ID: 12360471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholangiocarcinoma in primary sclerosing cholangitis: K-ras mutations and Tp53 dysfunction are implicated in the neoplastic development.
    Boberg KM; Schrumpf E; Bergquist A; Broomé U; Pares A; Remotti H; Schjölberg A; Spurkland A; Clausen OP
    J Hepatol; 2000 Mar; 32(3):374-80. PubMed ID: 10735605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures.
    Mody K; Jain P; El-Refai SM; Azad NS; Zabransky DJ; Baretti M; Shroff RT; Kelley RK; El-Khouiery AB; Hockenberry AJ; Lau D; Lesinski GB; Yarchoan M
    JCO Precis Oncol; 2022 Jun; 6():e2100510. PubMed ID: 35675577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 overexpression and K-ras gene mutations in primary sclerosing cholangitis-associated biliary tract cancer.
    Ahrendt SA; Rashid A; Chow JT; Eisenberger CF; Pitt HA; Sidransky D
    J Hepatobiliary Pancreat Surg; 2000; 7(4):426-31. PubMed ID: 11180865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraductal papillary neoplasms of the bile duct: stepwise progression to carcinoma involves common molecular pathways.
    Schlitter AM; Born D; Bettstetter M; Specht K; Kim-Fuchs C; Riener MO; Jeliazkova P; Sipos B; Siveke JT; Terris B; Zen Y; Schuster T; Höfler H; Perren A; Klöppel G; Esposito I
    Mod Pathol; 2014 Jan; 27(1):73-86. PubMed ID: 23828315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogenic KRAS-expressing organoids with biliary epithelial stem cell properties give rise to biliary tract cancer in mice.
    Kasuga A; Semba T; Sato R; Nobusue H; Sugihara E; Takaishi H; Kanai T; Saya H; Arima Y
    Cancer Sci; 2021 May; 112(5):1822-1838. PubMed ID: 33068050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromosome 9p21 loss and p16 inactivation in primary sclerosing cholangitis-associated cholangiocarcinoma.
    Ahrendt SA; Eisenberger CF; Yip L; Rashid A; Chow JT; Pitt HA; Sidransky D
    J Surg Res; 1999 Jun; 84(1):88-93. PubMed ID: 10334895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. K-ras mutations in the bile of patients with primary sclerosing cholangitis.
    Kubicka S; Kühnel F; Flemming P; Hain B; Kezmic N; Rudolph KL; Manns M; Meier PN
    Gut; 2001 Mar; 48(3):403-8. PubMed ID: 11171833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.
    Boerner T; Drill E; Pak LM; Nguyen B; Sigel CS; Doussot A; Shin P; Goldman DA; Gonen M; Allen PJ; Balachandran VP; Cercek A; Harding J; Solit DB; Schultz N; Kundra R; Walch H; D'Angelica MI; DeMatteo RP; Drebin J; Kemeny NE; Kingham TP; Simpson AL; Hechtman JF; Vakiani E; Lowery MA; Ijzermans JNM; Buettner S; Koerkamp BG; Doukas M; Chandwani R; Jarnagin WR
    Hepatology; 2021 Sep; 74(3):1429-1444. PubMed ID: 33765338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anatomical, histomorphological and molecular classification of cholangiocarcinoma.
    Kendall T; Verheij J; Gaudio E; Evert M; Guido M; Goeppert B; Carpino G
    Liver Int; 2019 May; 39 Suppl 1():7-18. PubMed ID: 30882996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Precancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma.
    Lewis JT; Talwalkar JA; Rosen CB; Smyrk TC; Abraham SC
    Am J Surg Pathol; 2010 Jan; 34(1):27-34. PubMed ID: 19898228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker.
    Chae H; Kim D; Yoo C; Kim KP; Jeong JH; Chang HM; Lee SS; Park DH; Song TJ; Hwang S; Kim KH; Song GW; Ahn CS; Lee JH; Hwang DW; Kim SC; Jang SJ; Hong SM; Kim TW; Ryoo BY
    Eur J Cancer; 2019 Oct; 120():31-39. PubMed ID: 31476489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next-generation sequencing mutation analysis on biliary brush cytology for differentiation of benign and malignant strictures in primary sclerosing cholangitis.
    Kamp EJCA; Dinjens WNM; van Velthuysen MF; de Jonge PJF; Bruno MJ; Peppelenbosch MP; de Vries AC
    Gastrointest Endosc; 2023 Mar; 97(3):456-465.e6. PubMed ID: 36252869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NGS of brush cytology samples improves the detection of high-grade dysplasia and cholangiocarcinoma in patients with primary sclerosing cholangitis: A retrospective and prospective study.
    Boyd S; Mustamäki T; Sjöblom N; Nordin A; Tenca A; Jokelainen K; Rantapero T; Liuksiala T; Lahtinen L; Kuopio T; Kytölä S; Mäkisalo H; Färkkilä M; Arola J
    Hepatol Commun; 2024 Apr; 8(4):. PubMed ID: 38551383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.